Linked Life Data

17510372

Source:http://linkedlifedata.com/resource/pubmed/id/17510372

Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17510372rdf:typepubmed:Citationlld:pubmed
pubmed-article:17510372lifeskim:mentionsumls-concept:C0278701lld:lifeskim
pubmed-article:17510372lifeskim:mentionsumls-concept:C0215407lld:lifeskim
pubmed-article:17510372lifeskim:mentionsumls-concept:C0017262lld:lifeskim
pubmed-article:17510372lifeskim:mentionsumls-concept:C0004083lld:lifeskim
pubmed-article:17510372lifeskim:mentionsumls-concept:C1707520lld:lifeskim
pubmed-article:17510372lifeskim:mentionsumls-concept:C0549193lld:lifeskim
pubmed-article:17510372lifeskim:mentionsumls-concept:C2911684lld:lifeskim
pubmed-article:17510372lifeskim:mentionsumls-concept:C0185117lld:lifeskim
pubmed-article:17510372pubmed:issue9lld:pubmed
pubmed-article:17510372pubmed:dateCreated2007-8-20lld:pubmed
pubmed-article:17510372pubmed:abstractTextCortactin and fascin-1 are important factors in tumor progression. We tested the hypothesis that cortactin and fascin-1 expression correlates with clinicopathological parameters of gastric adenocarcinoma. Immunohistochemical analysis of cortactin and fascin-1 was done using tissue microarrays of 100 surgical specimens, including 20 well-differentiated, 20 moderately differentiated, and 60 poorly differentiated gastric adenocarcinomas. Among the 20 well-differentiated gastric adenocarcinomas, 15 cases (75%) showed negative or weak staining (1+); 5 cases (25%) had moderate (2+) or strong (3+) cortactin expression. Among the 60 poorly differentiated gastric adenocarcinomas, more than three-quarters of the cases (76.7%) had moderate or strong cortactin expression; 14 cases (23.3%) had weak staining. Of 20 well-differentiated gastric adenocarcinoma cases, 14 (70%) showed negative or weak staining of fascin-1, whereas nearly one-third (30%) had moderate or strong expression. Among the 60 poorly differentiated gastric adenocarcinomas, 32 (53.3%) exhibited moderate or strong fascin-1 expression; fewer than half of the cases showed negative or weak staining. Higher intensity of cortactin and fascin-1 staining correlated directly with more-advanced cancer stages (TNM) and inversely with survival rates. Our findings suggest the possibility that pharmacological inhibitors of cortactin and fascin-1 activity may slow down tumor progression and prolong survival time in patients with gastric adenocarcinomas.lld:pubmed
pubmed-article:17510372pubmed:languageenglld:pubmed
pubmed-article:17510372pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17510372pubmed:citationSubsetIMlld:pubmed
pubmed-article:17510372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17510372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17510372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17510372pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17510372pubmed:statusMEDLINElld:pubmed
pubmed-article:17510372pubmed:monthSeplld:pubmed
pubmed-article:17510372pubmed:issn0022-1554lld:pubmed
pubmed-article:17510372pubmed:authorpubmed-author:JinJong-Shiaw...lld:pubmed
pubmed-article:17510372pubmed:authorpubmed-author:ChangWei-KuoW...lld:pubmed
pubmed-article:17510372pubmed:authorpubmed-author:YehMing-KungM...lld:pubmed
pubmed-article:17510372pubmed:authorpubmed-author:ChaoYou-ChenY...lld:pubmed
pubmed-article:17510372pubmed:authorpubmed-author:SheuLai-FaLFlld:pubmed
pubmed-article:17510372pubmed:authorpubmed-author:ChanDe-ChuanD...lld:pubmed
pubmed-article:17510372pubmed:authorpubmed-author:TsaiWen-Chiua...lld:pubmed
pubmed-article:17510372pubmed:authorpubmed-author:LinLi-FanLFlld:pubmed
pubmed-article:17510372pubmed:authorpubmed-author:CherngShiou-C...lld:pubmed
pubmed-article:17510372pubmed:issnTypePrintlld:pubmed
pubmed-article:17510372pubmed:volume55lld:pubmed
pubmed-article:17510372pubmed:ownerNLMlld:pubmed
pubmed-article:17510372pubmed:authorsCompleteYlld:pubmed
pubmed-article:17510372pubmed:pagination955-62lld:pubmed
pubmed-article:17510372pubmed:meshHeadingpubmed-meshheading:17510372...lld:pubmed
pubmed-article:17510372pubmed:meshHeadingpubmed-meshheading:17510372...lld:pubmed
pubmed-article:17510372pubmed:meshHeadingpubmed-meshheading:17510372...lld:pubmed
pubmed-article:17510372pubmed:meshHeadingpubmed-meshheading:17510372...lld:pubmed
pubmed-article:17510372pubmed:meshHeadingpubmed-meshheading:17510372...lld:pubmed
pubmed-article:17510372pubmed:meshHeadingpubmed-meshheading:17510372...lld:pubmed
pubmed-article:17510372pubmed:meshHeadingpubmed-meshheading:17510372...lld:pubmed
pubmed-article:17510372pubmed:meshHeadingpubmed-meshheading:17510372...lld:pubmed
pubmed-article:17510372pubmed:meshHeadingpubmed-meshheading:17510372...lld:pubmed
pubmed-article:17510372pubmed:meshHeadingpubmed-meshheading:17510372...lld:pubmed
pubmed-article:17510372pubmed:meshHeadingpubmed-meshheading:17510372...lld:pubmed
pubmed-article:17510372pubmed:meshHeadingpubmed-meshheading:17510372...lld:pubmed
pubmed-article:17510372pubmed:year2007lld:pubmed
pubmed-article:17510372pubmed:articleTitleAssociation of cortactin and fascin-1 expression in gastric adenocarcinoma: correlation with clinicopathological parameters.lld:pubmed
pubmed-article:17510372pubmed:affiliationDepartment of Pathology, Tri-Service General Hospital, National Defense Medical Center, Neihu, Taipei, Taiwan.lld:pubmed
pubmed-article:17510372pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17510372pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
entrez-gene:2017entrezgene:pubmedpubmed-article:17510372lld:entrezgene
entrez-gene:6624entrezgene:pubmedpubmed-article:17510372lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17510372lld:entrezgene
http://linkedlifedata.com/r...entrezgene:pubmedpubmed-article:17510372lld:entrezgene
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17510372lld:pubmed